Corbus Pharmaceuticals Holdings, Inc.
Long
Aggiornato

CRBP return to pre-covid?

708
The stock has been above $5 most of the time.
It is only that Lenbasaum, their leading drug, has failed in one of the clinical studies, that is why the stock plummeted in Sep 2020.
Nonetheless, they have couple others ongoing studies and they may have a chance to recover to pre-covid levels.
Before the September news their ratings were Buy and Outperform at $12, $22 and even $40 levels.

Mind the fundamentals and news.
Nota
Idea worked
And it may still have some potential

Declinazione di responsabilità

Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.